Amgen (AMGN) Price Target Trimmed at Morgan Stanley as Policy Risks Ease

Group 1 - Amgen Inc. is recognized as one of the 15 Best Blue-Chip Stocks with Growing Dividends, highlighting its reliability in providing income to investors [1] - Morgan Stanley has reduced its price target for Amgen from $329 to $304 while maintaining an Equal Weight rating, indicating a more optimistic outlook for the biopharma sector in 2026 as policy risks diminish [2] - Amgen announced a 6% increase in its quarterly dividend to $2.52 per share, marking 15 consecutive years of dividend increases, reinforcing its status as a dependable income stock [3] Group 2 - In Q3 2025, Amgen reported a 12% increase in revenue year-over-year, with volumes rising by 14%, and 16 of its products achieving double-digit growth [4] - The company is expanding across all four of its main therapeutic areas, with biosimilar revenue increasing over 50% year-over-year, approaching $3 billion annually [5] - Amgen plans to invest over $3 billion in US manufacturing this year, adding to the $40 billion already invested since 2017, demonstrating its commitment to growth and innovation [5]